Basic info
Industry
biotechnology research
Sectors
Biotechnology
secondary malignancy
Atara
CAR T
multiple sclerosis
progressive multiple sclerosis
biotechnology
immunology
CMV
stem cell transplant
PTLD
ATRA
nasopharyngeal carcinoma
immunotherapy
oncology
oncoviruses
bone marrow transplant
Allogeneic CD19 CAR T
Atara Bio
hematology
solid organ transplant
post-transplant lymphoproliferative disorder
off the shelf
solid tumors
regenerative medicine
cancer
Allogeneic EBV CAR T-cell platform
autoimmune diseases
lymphoproliferative disorders
gene therapy
MS
cytotoxic T lymphocytes
Health Care
Allogeneic CAR T-cell therapies
cell therapy
T-cells
secondary lymphoma
allogeneic
Therapeutics
immuno-oncology
EBV lymphoma
CTLs
Epstein-Barr virus
EBV
lymphoma
Cytomegalovirus
Date founded
2012
Funding rounds raised
Total raised
$39M
from 9 investors over 9 rounds
A
Atara Biotherapeutics raised $14M on January 10, 2014
Investors: Celgene, Domain Associates, Kleiner Perkins and DAG Ventures
A
Atara Biotherapeutics raised $39M on December 17, 2013
Investors: DAG Ventures, Kleiner Perkins, Celgene and Domain Associates
A
Atara Biotherapeutics raised $1M on March 31, 2013
Investors: Domain Associates